Clinical trial
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for…
NCT00159432 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00159432 |
|---|---|
| Title | Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
| Official title | Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
| Lead sponsor | University of Southern California, Other |
| Collaborators | Hoffmann-La Roche Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Oxaliplatin, Bevacizumab, Capecitabine |
| Enrollment | 63 |
| Start date | Feb 1, 2005 |
| Primary completion | Jun 1, 2009 |
| Completion | Mar 1, 2013 |
| First posted | Sep 12, 2005 |
| Last update posted | Jul 29, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: